阿尔茨海默病患者便中的Aβ聚合物升高:一项概念验证研究
Marlene Pils1,2, Alexandra Dybala3, Anja Schaffrath1
1Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum Jülich, 52428, Jülich, Germany.
Alzheimer's research & therapy
|October 14, 2024
概括
在阿尔茨海默病 (AD) 患者中可以检测出便中的粉样蛋白-β (Aβ) 聚合物. 便中的升高水平表明AD诊断的潜在非侵入性生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物发现发现
- 胃肠病学 胃肠病学
背景情况:
- 阿尔茨海默病 (AD) 的特点是粉样β (Aβ) 和tau病理.
- 一个假设表明Aβ聚合物被清除到肠道.
研究的目的:
- 调查人类便中Aβ聚合物的存在和度.
- 评估便Aβ聚合物作为AD的潜在诊断生物标志物.
主要方法:
- 使用了基于表面的光强度分布分析 (sFIDA).
- 分析了26名AD患者和31名健康对照 (HC) 的便样本.
主要成果:
- 在所有参与者的便中检测到Aβ聚合物.
- 与HC相比,AD患者的便Aβ总度明显高于AD患者.
- 该试验显示AD检测的特异性为90.3%,灵敏度为53.8%.
结论:
- 便Aβ聚合物显示出作为阿尔茨海默病诊断的非侵入性生物标志物具有前途.
- 需要进一步的研究来确定这些聚合物的分泌途径 (肝脏/胆汁与肠道神经系统).
相关概念视频
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Alzheimer's Disease: Treatment
166
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
166


